{"filings":[{"id":98384,"accession_number":"0001437749-26-013646","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.","Cash bonuses approved: ~$1.9M for Green, ~$0.5M each for Hrdy and Monich to cover estimated taxes from award changes.","Expected Q2 2026 expense of $9.4M: ~$6.5M non-cash accelerated equity comp and ~$2.9M cash bonus expense.","Effective tax rate impacted by non-deductibility of amounts; future period charges eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98383,"accession_number":"0001437749-26-013641","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q1 revenue up 4% to $34.8M; TRCV record $152.1M (+13% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.2M ($0.14 diluted EPS); adjusted net income $4.6M ($0.21 adjusted diluted EPS).","Adjusted EBITDA $9.4M (27% of revenue); cash flow from operations $7.2M up 8% YoY.","Total Recurring Contract Value (TRCV) $152.1M, up 13% YoY, sixth consecutive quarterly increase.","Company signed the largest deal in its 45-year history; new sales and retention reached multi-year highs.","Free cash flow $5.4M (15% of revenue); revenue $34.8M, first YoY growth since 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":34803000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98382,"accession_number":"0001437749-26-012850","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"NRC Health declassifies board, formalizes name change; CFO restricted stock amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to NRC Health from National Research Corp; 'NRC' ticker unchanged; no shareholder vote required.","Board declassified: all directors will face annual elections; five directors resigned residual terms effective before June 23, 2026 meeting.","Resigning directors: Berwick, Green, Hays, Lockhart, Nunnelly; all seven incumbents nominated for reelection at 2026 annual meeting.","CFO Shane Harrison's restricted stock award (172,000 shares, Sept 2025) amended to permit voting and dividends on unvested shares.","Amended Bylaws set max board size at 12, update meeting/notice deadlines, and formalize Chair position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113805,"accession_number":"0001437749-26-006945","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NRC Health TRCV reaches all-time high of $152M, up 13% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TRCV surpassed $152 million as of March 4, 2026, a new all-time high for NRC Health.","TRCV increased approximately 6% from Q4 2025 and 13% year-over-year.","CEO Trent Green attributed the milestone to customer confidence and platform value.","The update does not reflect complete financial results for Q1 ending March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113804,"accession_number":"0001437749-26-002726","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q4 2025 revenue $35.2M; TRCV up 8% YoY to $144.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income $1.8M ($0.08 diluted EPS); adjusted net income $3.4M ($0.16 diluted EPS).","Adjusted EBITDA $8.7M (25% of revenue); operating cash flow $7.2M, up 13% YoY.","Full-year 2025 revenue $137.4M; GAAP net income $11.6M ($0.50 EPS); adjusted net income $20.7M ($0.93 EPS).","TRCV of $144.1M grew 8% YoY and sequentially for the fifth consecutive quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":50.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":137390000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130215,"accession_number":"0001437749-25-031819","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q3 2025: TRCV up 8% to $141.7M; Adj EBITDA +11% YoY to $10.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.6M (+2% QoQ); GAAP net income $4.1M (12% of revenue); Adj net income $5.0M (14% of revenue).","GAAP EPS $0.18; adjusted EPS $0.23 on 22.1M diluted shares.","Cash from operations $13.8M (+46% YoY), representing 40% of total revenue.","Total Recurring Contract Value (TRCV) $141.7M, up 8% YoY; fourth consecutive quarterly growth.","CEO Trent Green cited strong sales and improved customer retention as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":102196000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146773,"accession_number":"0001437749-25-027942","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NRC Health names Shane Harrison CFO effective Sept 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shane Harrison appointed Executive VP and CFO, succeeding Michael D. Hays as principal financial officer.","Annual base salary of $400,000; $100,000 signing bonus subject to pro-rated repayment if terminated within one year.","Grant of 172,000 restricted shares vesting over three years; accelerated vesting on double-trigger change in control.","Harrison most recently SVP Finance and IR at PowerSchool; prior roles at NAVEX Global and FLIR Systems."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146772,"accession_number":"0001437749-25-023676","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q2 2025: TRCV grows 2% sequentially; net margin 0% on exec comp; adj EBITDA margin 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TRCV grew 2% sequentially, third consecutive quarter of growth and highest since Q1 2021.","Net margin 0% due to non-recurring executive compensation; adjusted EBITDA margin 30%.","Declared $0.12 quarterly dividend; payable Oct 10, 2025 to holders of record Sept 26, 2025.","Repurchased 381,736 shares at $14.96 avg in Q2; $16.1M returned to shareholders YTD.","New CEO Trent Green reinstated quarterly earnings call; cites strong customer feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":67588000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165208,"accession_number":"0001437749-25-015965","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"National Research shareholders approve 2025 Omnibus Incentive Plan, elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Donald M. Berwick and Stephen H. Lockhart elected as directors for three-year terms.","KPMG LLP ratified as independent auditor for 2025 with 21,710,551 votes for.","Say-on-pay advisory vote passed with 20,655,974 for, 217,494 against.","2025 Omnibus Incentive Plan approved with 16,852,672 for, 4,017,318 against, replacing prior plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165207,"accession_number":"0001437749-25-013363","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"National Research Corporation Reports Q1 2025 Results and Announces Share Repurchase Program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total recurring value contract value increased sequentially for second consecutive quarter.","Board approved repurchase of up to one million additional shares of common stock.","Declared quarterly cash dividend of $0.12 per share payable July 11, 2025.","Operating expenses declined in the first quarter of 2025.","Trent Green to join as CEO in June 2025; introductory calls available June 9-10."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":33551000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165206,"accession_number":"0001437749-25-012697","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research designates CEO Hays as interim PFO, appoints Freeman as CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Michael D. Hays designated principal financial officer; will serve as PEO and PFO until Trent Green becomes CEO on June 1, 2025.","Jordan N. Freeman appointed Chief Accounting Officer and principal accounting officer, effective April 18, 2025.","No compensation changes were made in connection with either appointment.","Freeman previously served in accounting leadership roles at Nelnet and as a senior audit associate at Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165205,"accession_number":"0001437749-25-011529","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NRC adjusts exec compensation ahead of CEO transition; COO gets 100k share grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trent Green to become CEO and director effective June 1, 2025, as previously announced.","COO Helen Hrdy received 100,000 restricted shares; cash bonus of 66 2/3% of share value; base salary stays $400k.","Hrdy forfeited unvested performance option for 100k shares; prior severance and 2024 LTIP terminated.","Same compensation changes apply to Chief Corporate Development Officer Andrew Monnich.","CEO Michael Hays' compensation unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182886,"accession_number":"0001008886-25-000033","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NRC appoints Trent Green as CEO effective June 1, 2025; Hays becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trent Green named CEO effective June 1, 2025; current CEO Mike Hays transitions to Chairman.","Green's compensation: $1.25M base salary, 500,000 restricted shares, cash signing bonus equal to 66.67% of share value.","Linda Stacy appointed Interim Principal Financial Officer through March 31, 2025 at $150/hour.","Green most recently CEO of Amazon One Medical; previously COO at Legacy Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182885,"accession_number":"0001437749-25-003231","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"National Research enters $140M credit facility ($30M revolver + $110M term loan); $62.4M drawn at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit agreement dated Feb 6, 2025 amends and restates 2020 facility with First National Bank of Omaha.","Revolving credit facility of $30M; $3.5M outstanding at close; matures in 3 years.","Delayed draw term loan of $110M with accordion up to $25M; $62.4M drawn; matures in 5 years.","Interest at Term SOFR + 2.25% to 2.75% based on leverage; covenants: fixed charge coverage ≥1.10x, leverage ≤3.50x.","Facility secured by substantially all assets; restricts stock repurchases and acquisitions subject to exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182884,"accession_number":"0001437749-25-001928","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.","Net indebtedness $58.5M; total recurring contract value $133.2M at Dec 31, 2024.","Returned $10.1M to shareholders: $7.3M in stock repurchases (393k shares) plus $0.12/share dividend.","Chief Product Technology Officer Chrisophe Louvion resigned effective Jan 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":143060000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199471,"accession_number":"0001437749-24-035132","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research CFO/PAO Linda Stacy to retire effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Linda Stacy notified company of retirement as Secretary, Principal Financial Officer, and Principal Accounting Officer.","Retirement effective December 31, 2024; no successor named yet.","Stacy served over 18 years; Board expressed gratitude for her service.","Departure creates a vacancy in key financial and accounting leadership roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199470,"accession_number":"0001437749-24-032151","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q3 revenue falls 5.5% to $35.8M; EPS drops to $0.24 from $0.32","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.8M vs $37.9M a year ago; diluted EPS $0.24 vs $0.32.","Net indebtedness $50.2M at Sept 30, 2024; Total Recurring Contract Value $131.6M.","Returned $11.5M to stockholders: $8.6M share repurchases (395k shares) and $2.9M dividends.","Board declared $0.12 quarterly dividend payable Jan 10, 2025 to holders of record Dec 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":106154000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199469,"accession_number":"0001437749-24-031195","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research appoints Helen L. Hrdy as COO effective Oct 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Helen L. Hrdy, 60, appointed Chief Operating Officer on October 14, 2024.","Previously served as Chief Customer Officer since January 2024 and Chief Growth Officer from Jan 2020 to Jan 2024.","Hrdy has held various roles with the company since 2000, including Senior Vice President, Customer Success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215505,"accession_number":"0001437749-24-024947","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"NRC Health Q2 revenue $35M, EPS $0.26; amends credit; acquires NOBL Health","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue ~$35M vs ~$36M YoY; diluted EPS $0.26 vs $0.29 YoY; TRCV $138M at June 30.","Credit agreement amended: maturity extended to May 2027; term loans bear SOFR+2.35% with 10-year amort.","Acquired NOBL Health on July 15 for ~$6M cash + up to $1M earnout; NOBL had ~$2M TRCV.","Board declared $0.12/share quarterly dividend, payable Oct 11, record Sep 27.","~1.1M shares remain under repurchase plan; no buybacks in Q2 pending amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":70334000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234841,"accession_number":"0001437749-24-016208","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NRC shareholders elect directors, ratify KPMG, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael D. Hays re-elected with 97.1% of votes cast; John N. Nunnelly with 91.2%.","KPMG ratified as independent auditor for 2024 with 99.2% approval.","Non-binding advisory vote on executive compensation approved with 98.9% support.","Approximately 96% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234840,"accession_number":"0001437749-24-015131","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NRC Health appoints Linda Stacy as PFO; Q1 dividend $0.12; $40M net debt; no GAAP results disclosed","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Linda Stacy appointed Principal Financial Officer effective May 7, 2024; retains roles as PAAO and Secretary.","Quarterly cash dividend of $0.12/share declared, payable July 15, 2024 to holders of record June 28, 2024.","Q1 2024 returned $18M to stockholders via dividends and share repurchases; $4M invested in innovation.","Net debt ~$40M; available liquidity includes $23M line of credit and $56M delayed draw term facility.","Press release provides no GAAP revenue or EPS figures; CEO cites upcoming AI features and expanded product suite."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":35313000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}